Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill for diabetes shows promise in Real-World study

NCT ID NCT06269120

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study will follow about 470 adults with type 2 diabetes who are starting oral semaglutide as part of their normal care. Researchers will track changes in blood sugar (HbA1c) and body weight over 5 to 7 months. The goal is to see how well the medication works when prescribed by cardiologists or diabetologists in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral semaglutide
What this could lead to
If successful, this could show that oral semaglutide helps many patients with type 2 diabetes achieve better blood sugar control and weight loss in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also short-term (5-7 months) and may not reflect long-term benefits or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

243 people

The number who actually took part.

Started

Sep 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participant diagnosed with T2D and without any prior or current use of oral semaglutide.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/LAR and the treating physician based on local label before and independently from the decision to include the patient in this study. * Male or female, adults above or equal to 18 years of age at the time of signing informed consent. * Diagnosed with type 2 diabetes mellitus. * Patient on metformin (Met) with or without modern oral antidiabetic (MOAD, that is Dipeptidyl Peptidase-4 Inhibitor \[DPP4i\] or/and Sodium-glucose cotransporter-2 Inhibitor \[SGLT2i\]) with or without insulin therapy. * Available HbA1c value \> 7.0% within 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice. Exclusion Criteria: * Previous participation in this study (defined as having given informed consent in this study earlier). * Treatment with any investigational drug within 30 days prior to enrolment into the study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Glucagon like peptide -1 receptor agonist (GLP1-RA) treatment within 90 days prior to the Treatment Initiation visit (V1). * Patients diagnosed with type 1 diabetes mellitus. * Female who is known to be pregnant, undergoing fertility treatment, breastfeeding or intends to become pregnant during the study duration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Bajcsy-Zsilinszky Kórház

    Budapest, 1106, Hungary

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház

    Miskolc, 3526, Hungary

  • Bács-Kiskun Vármegyei Oktatókórház Invazív Kardiológiai Osztály

    Kecskemét, 6000, Hungary

  • Békés Vármegyei Központi Kórház

    Gyula, Bekes County, 5700, Hungary

  • Békés Vármegyei Központi Kórház

    Békéscsaba, 5600, Hungary

  • Coromed SMO Kft.

    Pécs, 7623, Hungary

  • DE KK Kardiológiai és Szívsebészeti klinika

    Debrecen, 4032, Hungary

  • Debreceni Egyetem Belgyógyászati Klinika

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Gottsegen György Országos Kardiológiai Intézet

    Budapest, 1096, Hungary

  • Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet, Kardiológiai Osztály

    Eger, 3300, Hungary

  • Háziorvosi Rendelő

    Felsőrajk, 8767, Hungary

  • Jahn Ferenc Dél-pesti Kórház és Rendelőintézet, Diabetológia

    Budapest, 1204, Hungary

  • Jósa András Oktatókórház

    Nyíregyháza, 4400, Hungary

  • Nyírő Gyula Országos Pszichiátriai és Addiktológiai Intézet, Diabetológia Szakrendelés

    Budapest, 1135, Hungary

  • Petz Aladar Megyei Oktato Korhaz

    Győr, 9024, Hungary

  • Pécsi Tudományegyetem Általános Orvostudományi Kar Klinikai Központ II.sz. Belgyógyászati Klinika és Nephrológiai Centrum

    Pécs, H-7623, Hungary

  • Semmelweis Egyetem, Általános Orvostudományi Kar Városmajori Szív- és Érgyógyászati Klinika

    Budapest, 1122, Hungary

  • Siklósi Kórház, Diabetológia

    Siklós, 7801, Hungary

  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

    Szeged, 6725, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.